Retatrutide

Retatrutide is a next-generation investigational peptide engineered as a triple hormone receptor agonist, simultaneously targeting GLP-1, GIP, and glucagon receptors. This triple-action mechanism is designed to deliver comprehensive metabolic regulation beyond what single- or dual-agonist compounds achieve.

Each unit is supplied as a single pre-filled ready-mixed sensiPen™️ cartridge containing 50 mg of Retatrutide in 3 ml of stabilized solution — no reconstitution required. The proprietary Oxygen-Controlled Stability Platform preserves peptide integrity in liquid form for research protocols. In research settings, Retatrutide has been studied for its potential to significantly reduce adiposity, improve glycaemic control, and enhance overall energy homeostasis. The peptide functions by amplifying insulin secretion in a glucose-dependent manner, suppressing glucagon release postprandially, slowing gastric emptying, and centrally reducing appetite drive. The addition of glucagon-receptor agonism introduces a unique thermogenic and hepatic lipid-mobilization component not observed with GLP-1-only analogues.

Researchers have documented its role in improving lipid profiles, reducing markers of non-alcoholic fatty liver disease, and supporting cardiovascular risk-factor reduction in preclinical models. Administered once weekly in research protocols due to its extended half-life, Retatrutide represents a cutting-edge tool for studying obesity, metabolic syndrome, and type-2 diabetes pathophysiology. For research purposes only.